About Tasly and the Partnership
Tasly is one of China's largest pharmaceutical companies and is China's 2nd producer of TCMs, which are derived from plants. Its lead drug, Tasly Cardiotonic Pill, is the #1 selling TCM in China for the past seven years. In 2011, Tasly recorded revenues of 6.5 billion RMB with a 10 year compounded growth rate in excess of 20%. Tasly also has operations in the United States, Africa, South East Asia, and the UK.
SemBioSys is a health and wellness company that utilizes its renewable, patented plant seed oilbody and plant-based protein expression technology platforms to develop and produce high-value proteins and oils to make nutritional products and drug candidates.
SemBioSys is entitled to 30% ownership and profit sharing of the Joint Ventures profits for contributing select intellectual property. Tasly will contribute 100 per cent of the cost of the Joint Venture's global research, development and product commercialization. Further, Tasly will facilitate preclinical, clinical, regulatory services, manufacturing and commercial expertise, and utilize its significant sales force to commercialize the Joint Venture's products in China. Its sales force covers approximately 25,000 Chinese hospitals, retail pharmacies and direct to consumer markets with a total of 1,500 representatives.